Convalescent Plasma Coupled With Medications for the Treatment of a Severe COVID-19 Patient: Drugs Analysis and Pharmaceutical Care Based on the Newly Established Guidelines for COVID-19 Remedy-Reference-Cited by-同舟云学术

Convalescent Plasma Coupled With Medications for the Treatment of a Severe COVID-19 Patient: Drugs Analysis and Pharmaceutical Care Based on the Newly Established Guidelines for COVID-19 Remedy

Published:2020-06-24 Issue: Volume:11 Page:
ISSN:1663-9812
Container-title:Frontiers in Pharmacology
language:
Short-container-title:Front. Pharmacol.

Author:

Wang Ying,Zhang Yang,Yu Qian,Zhu Kun

Publisher

Frontiers Media SA

Subject

Pharmacology (medical),Pharmacology

Reference43 articles.

1. Therapeutic Inhibitors of Platelet Aggregation ?from Aspirin to Integrin Blockersf;Ahrens;Transfus. Med. Hemother.,2007

2. Feasibility of Using Convalescent Plasma Immunotherapy for MERSCoV Infection, Saudi Arabia;Arabi;Emerg. Infect. Dis.,2016

3. Immune plasma for the treatment of severe influenza: an open-label, multicentre, phase 2 randomised study [published correction appears in Lancet Respir Med;Beigel;Lancet Respir. Med.,2017

4. Discussion on clinical pharmaceutical service model in prevention and treatment of corona virus disease 2019;Bian;Chin. J. New Drugs Clin. Rem.,2020

5. Pharmaco-epidemiological study of the course of influenza and other acute respiratory viral infections in risk groups;Bulgakova;Ter. Arkh.,2017

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Regulatory Pathway for the Approval of Novel Candidate Vaccine;International Journal of Pharmaceutical Investigation;2024-04-02

2. Convalescent plasma for people with COVID-19: a living systematic review;Cochrane Database of Systematic Reviews;2023-05-10

3. Convalescent plasma for people with COVID-19: a living systematic review;Cochrane Database of Systematic Reviews;2023-02-01

4. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review;Cochrane Database of Systematic Reviews;2021-05-20

5. Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine;New England Journal of Medicine;2020-12-10